Oppenheimer Asset Management Inc. Purchases 8,779 Shares of Bristol Myers Squibb Company $BMY

Oppenheimer Asset Management Inc. grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 1.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 495,604 shares of the biopharmaceutical company’s stock after purchasing an additional 8,779 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Bristol Myers Squibb were worth $28,557,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Norges Bank bought a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $1,947,272,000. AQR Capital Management LLC boosted its holdings in Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after buying an additional 16,332,924 shares during the period. Bank of New York Mellon Corp boosted its holdings in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after buying an additional 7,837,485 shares during the period. Geode Capital Management LLC grew its stake in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Finally, Man Group plc raised its holdings in Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after acquiring an additional 5,503,391 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on BMY. Sanford C. Bernstein upgraded Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 5th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Roth Capital began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective on the stock. Piper Sandler assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating on the stock. Finally, JPMorgan Chase & Co. raised their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $63.86 on Friday. The company’s 50 day simple moving average is $59.56 and its two-hundred day simple moving average is $58.97. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.10. The stock has a market capitalization of $130.45 billion, a PE ratio of 14.07, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.96 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.